RxDoctor Payments Data

Jaime Sanchez, MD

Cardiovascular Disease · Hialeah, FLNPI 1154390441

Payments from drug & device makers

$14,645in general payments, 2019–2025

Across 303 payments — averaging $48.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Biotronik Inc.$4K
  • Novartis$832
  • Boston Scientific$659
  • Pfizer$456
  • Amgen$398
  • plus $4K from 34 others

What the payments were for

  • Travel & lodging$1091%
  • Food & beverage$14,49599%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,645 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$132,046
Medicare patients
177
Services billed
1,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban381$461,505
EntrestoSacubitril/Valsartan296$333,468
JardianceEmpagliflozin141$164,139
FarxigaDapagliflozin Propanediol156$144,010
XareltoRivaroxaban79$98,874
Repatha SureclickEvolocumab20$20,123
BrilintaTicagrelor31$18,377
VascepaIcosapent Ethyl24$11,648
Metoprolol Succinate614$3,811
Rosuvastatin Calcium218$2,347
Chlorthalidone154$2,302
Amiodarone Hcl89$2,000
Atorvastatin Calcium422$1,964
SotalolSotalol Hcl62$1,926
Losartan Potassium323$1,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$456$461,505381 claims
NovartisEntresto$832$333,468296 claims
Boehringer IngelheimJardiance$377$164,139141 claims
AstraZenecaFarxiga, Brilinta$266$162,387187 claims
Johnson & JohnsonXarelto$231$98,87479 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →